LAG-3 expression in the inflammatory microenvironment of glioma

PURPOSE: Immune modulatory therapies including immune checkpoint inhibitors have so far failed to result in clinically meaningful efficacy in glioma. We aimed to investigate lymphocyte activation gene 3 (LAG-3), an inhibitory receptor on immune cells and target of second-generation immune checkpoint...

Descripción completa

Detalles Bibliográficos
Autores principales: Mair, Maximilian J., Kiesel, Barbara, Feldmann, Katharina, Widhalm, Georg, Dieckmann, Karin, Wöhrer, Adelheid, Müllauer, Leonhard, Preusser, Matthias, Berghoff, Anna S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084780/
https://www.ncbi.nlm.nih.gov/pubmed/33651248
http://dx.doi.org/10.1007/s11060-021-03721-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084780/
https://www.ncbi.nlm.nih.gov/pubmed/33651248
http://dx.doi.org/10.1007/s11060-021-03721-x

Ejemplares similares